Glenmark Pharmaceuticals Ltd
GLENMARK NSE
Glenmark Pharmaceuticals Ltd
Healthcare F&ONSE: GLENMARK BSE: 532296 Pharmaceuticals
Key Fundamentals
MidcapPharmaceuticalsHealthcareMarket Cap
₹65,530 Cr
Volatility
Moderate
P/E Ratio
36.18
EBITDA
₹5,033 Cr
Return on Equity
12.96%
Debt to Equity
0.06
Book Value
₹372.47
EPS
₹0
52W High
₹2,474
52W Low
₹1,792.6
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Glenmark Pharmaceuticals Ltd insights
60 extracted metrics + investor summaries across FY00–FY27.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 19.4% CAGR over last 5 years
Weaknesses
4- The company has delivered a poor sales growth of 9.19% over past five years.
- Company has a low return on equity of -3.28% over last 3 years.
- Debtor days have increased from 85.2 to 107 days.
- Working capital days have increased from 41.2 days to 80.5 days
Growth Rate
Revenue Growth
29.83% ↗
Net Income Growth
30.07% ↘
Cash Flow Change
516.27% ↗
ROE
9.55% ↘
ROCE
1.76% ↘
EBITDA Margin (Avg.)
57.22% ↗
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 5d agoAI opinion · based on fundamentals
Risk medium
Glenmark Pharmaceuticals trades at a market cap of ₹64,841 Cr with a PE of 35.7x, reflecting a sharp profit turnaround with TTM profit growth of 134% and last-year ROE jumping to 30%. However, the company's 3-year average ROE remains negative at -1%, and working capital efficiency has deteriorated significantly.
Bull Case 7
- TTM compounded profit growth of 134% signals a strong earnings turnaround from prior years of weak profitability
- Company is almost debt-free, having materially reduced its leverage, improving balance sheet resilience
- Last-year ROE surged to 30%, a dramatic improvement from the 3-year average of -1%
- 5-year compounded profit CAGR of 26% demonstrates sustained earnings recovery over the medium term
- Stock CAGR of 42% over 3 years reflects strong market re-rating on improving fundamentals
- TTM sales growth of 33% marks a significant acceleration from the 5-year sales CAGR of just 9%
- 10-year ROE average of 8% suggests the business has historically generated reasonable returns when operating normally
Bear Case 8
- 3-year average ROE of -1% indicates the company destroyed shareholder value over a prolonged period before the recent recovery
- Debtor days increased from 85.2 to 107 days, signaling deteriorating collection efficiency and potential revenue quality concerns
- Working capital days nearly doubled from 41.2 to 80.5 days, tying up more capital in operations
- 5-year sales CAGR of only 9.19% reflects structurally modest top-line growth relative to the PE of 35.7x
- PE of 35.7x is elevated for a pharma company with inconsistent historical profitability, leaving limited margin of safety
- Price-to-book of 6.1x is relatively high, pricing in significant future growth that may not materialize if sales growth reverts to historical trends
- Dividend yield of just 0.22% offers negligible income return to shareholders
- 10-year sales CAGR of only 8% suggests the company has struggled to grow the top line meaningfully over a full business cycle
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 19h ago Headwinds 1
- $15.28M US antitrust settlement Aug 11
Glenmark settled antitrust litigation with Humana for $15.28 million. The provision was already accounted for in financials, limiting future P&L impact but highlighting ongoing US legal exposure.
Positives 4
- Q1FY27 net profit surges 925% Aug 3
Consolidated net profit jumped 925% YoY to ₹4.83B on revenue of ₹40.2B (vs ₹32.6B). EBITDA margins expanded to 19.51% from 17.78%, driven by operational efficiencies and absence of prior-year exceptional losses.
- Targets $100M quarterly US revenue Aug 5
US contributes ~25% of sales with quarterly revenue projected to exceed $100M. Guided 12%-15% India growth, 21%-22% FY27 operating margins, zero gross debt, and ~$70M IGI investments over 2-3 years.
- Sugammadex launched in US Jul 28
Glenmark launched generic Sugammadex Injection in the US, targeting a $1.6 billion market opportunity. The product is bioequivalent to Merck's BRIDION.
- RYALTRIS pediatric FDA approval Jul 21
US FDA approved RYALTRIS Nasal Spray for children aged 6-11, expanding the addressable market for Seasonal Allergic Rhinitis treatment.
Neutral 4
- 48th AGM set for Sep 11 Aug 7
Glenmark scheduled its 48th AGM for September 11, 2026 via VC/OAVM, with remote e-voting between September 8 and 10.
- Investor meets in Aug-Sep Aug 7
Company announced physical group and one-on-one sessions at four major financial conferences in Mumbai during August and September 2026.
- ₹16.97Cr block trade on NSE Jul 20
Approximately 75,821 shares traded in a block deal at ₹2,238 per share, totaling ₹16.97 crores, indicating institutional activity.
- Q1 FY27 earnings call hosted Aug 3
Audio recording of the Q1 FY27 earnings call held on August 3, 2026 was uploaded to the company website and disclosed to exchanges.
TL;DR: Glenmark is delivering strong momentum with a 925% YoY profit surge in Q1FY27, expanding margins, and ambitious US revenue targets exceeding $100M quarterly. New US launches (Sugammadex, RYALTRIS pediatric) strengthen the pipeline in large markets. The $15.28M Humana settlement is a manageable headwind already provisioned. The trend is clearly improving, with margin expansion, debt reduction to zero, and growing US generics franchise providing a bullish setup into FY27.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,036 | 3,207 | 2,507 | 3,063 | 3,244 | 3,434 | 3,388 | 3,256 | 3,264 | 6,047 | 3,901 | 3,771 | 4,018 |
| Expenses | 2,599 | 2,745 | 2,715 | 2,559 | 2,656 | 2,832 | 2,787 | 2,695 | 2,684 | 3,687 | 3,031 | 3,008 | 3,214 |
| Operating Profit | 437 | 462 | -209 | 504 | 588 | 602 | 600 | 561 | 581 | 2,360 | 870 | 763 | 805 |
| OPM % | 14% | 14% | -8% | 16% | 18% | 18% | 18% | 17% | 18% | 39% | 22% | 20% | 20% |
| Other Income | -32 | -205 | 87 | 351 | 31 | 39 | 31 | -361 | -297 | -1,184 | -140 | -184 | 66 |
| Interest | 112 | 121 | 134 | 149 | 40 | 48 | 52 | 67 | 58 | 66 | 41 | 43 | 54 |
| Depreciation | 142 | 141 | 147 | 151 | 118 | 120 | 123 | 125 | 130 | 141 | 154 | 148 | 173 |
| PBT | 151 | -6 | -403 | 555 | 462 | 473 | 456 | 8 | 96 | 967 | 534 | 388 | 643 |
| Tax % | -14% | 997% | -18% | 319% | 26% | 25% | 24% | 45% | 51% | 37% | 24% | 22% | 25% |
| Net Profit | 173 | -62 | -331 | -1,214 | 340 | 354 | 348 | 4 | 47 | 610 | 403 | 301 | 483 |
| EPS in Rs | 5.31 | -2.9 | -12.45 | -43.17 | 12.06 | 12.55 | 12.33 | 0.16 | 1.66 | 21.63 | 14.29 | 10.68 | 17.11 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,563 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 11,583 | 11,813 | 13,322 | 16,983 | 17,737 |
| Expenses | 5,348 | 6,125 | 7,043 | 7,457 | 8,280 | 8,942 | 8,860 | 9,978 | 9,948 | 10,618 | 10,970 | 12,410 | 12,940 |
| Operating Profit | 1,214 | 1,437 | 2,037 | 1,617 | 1,586 | 1,699 | 2,084 | 2,327 | 1,635 | 1,195 | 2,351 | 4,572 | 4,797 |
| OPM % | 18% | 19% | 22% | 18% | 16% | 16% | 19% | 19% | 14% | 10% | 18% | 27% | 27% |
| Other Income | -180 | 20 | -44 | 89 | 375 | 191 | 95 | -101 | -10 | 336 | -259 | -1,805 | -1,443 |
| Interest | 190 | 179 | 237 | 286 | 335 | 377 | 353 | 298 | 349 | 516 | 207 | 209 | 204 |
| Depreciation | 300 | 234 | 264 | 302 | 326 | 417 | 444 | 487 | 569 | 582 | 486 | 573 | 617 |
| PBT | 544 | 1,044 | 1,491 | 1,119 | 1,301 | 1,096 | 1,382 | 1,441 | 707 | 434 | 1,399 | 1,985 | 2,533 |
| Tax % | 61% | 29% | 26% | 28% | 29% | 29% | 30% | 31% | 47% | 430% | 25% | 31% | — |
| Net Profit | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 994 | 377 | -1,434 | 1,047 | 1,362 | 1,798 |
| EPS in Rs | 7.72 | 26.33 | 39.29 | 28.49 | 32.78 | 27.5 | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 | 48.26 | 63.71 |
| Div. Payout % | 26% | 8% | 5% | 7% | 6% | 9% | 7% | 7% | 24% | -5% | 7% | 10% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
| Reserves | 1,756 | 3,601 | 4,464 | 5,135 | 5,577 | 6,042 | 7,036 | 9,058 | 9,446 | 7,820 | 8,821 | 10,484 |
| Borrowings | 3,800 | 3,988 | 4,724 | 4,639 | 4,449 | 4,869 | 4,986 | 3,962 | 4,608 | 1,231 | 2,473 | 594 |
| Other Liabilities | 2,726 | 2,575 | 2,548 | 2,793 | 3,235 | 3,729 | 3,524 | 4,003 | 5,289 | 5,279 | 4,669 | 8,801 |
| Total Liabilities | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,371 | 14,358 | 15,991 | 19,907 |
| Fixed Assets | 2,015 | 2,594 | 2,755 | 3,030 | 3,670 | 5,029 | 5,129 | 5,887 | 5,422 | 4,210 | 4,487 | 5,915 |
| CWIP | 477 | 543 | 708 | 1,122 | 1,399 | 1,222 | 1,382 | 1,010 | 1,190 | 662 | 835 | 909 |
| Investments | 17 | 17 | 16 | 15 | 30 | 25 | 25 | 50 | 45 | 790 | 56 | 42 |
| Other Assets | 5,799 | 7,039 | 8,285 | 8,429 | 8,190 | 8,393 | 9,040 | 10,105 | 12,715 | 8,697 | 10,613 | 13,041 |
| Total Assets | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,371 | 14,358 | 15,991 | 19,907 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 482 | 345 | 657 | 1,648 | 1,324 | 1,392 | 1,131 | 1,109 | 625 | -265 | -828 | 3,445 |
| Investing | -712 | -950 | -1,001 | -1,003 | -883 | -774 | -662 | -316 | -515 | 4,387 | 58 | -1,237 |
| Financing | 199 | 699 | 543 | -468 | -739 | -445 | -442 | -520 | -77 | -3,906 | 787 | -2,709 |
| Net Cash Flow | -31 | 93 | 199 | 177 | -297 | 174 | 28 | 272 | 32 | 215 | 17 | -501 |
| Free Cash Flow | -56 | -544 | -76 | 625 | 712 | 616 | 456 | 320 | 75 | -1,162 | -1,576 | 2,090 |
| CFO/OP | 66 | 57 | 67 | 124 | 111 | 109 | 79 | 72 | 77 | 65 | -6 | 92 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 140 | 120 | 97 | 94 | 81 | 83 | 86 | 92 | 115 | 57 | 92 | 107 |
| Inventory Days | 247 | 249 | 299 | 244 | 244 | 211 | 230 | 208 | 203 | 208 | 254 | 264 |
| Days Payable | 379 | 308 | 243 | 225 | 241 | 210 | 226 | 190 | 172 | 210 | 256 | 288 |
| Cash Conversion Cycle | 8 | 61 | 152 | 113 | 85 | 84 | 90 | 110 | 147 | 56 | 90 | 83 |
| Working Capital Days | 47 | 51 | 125 | 99 | 64 | 54 | 67 | 65 | 141 | -2 | 44 | 81 |
| ROCE % | 16% | 19% | 21% | 15% | 15% | 14% | 15% | 16% | 10% | 12% | 19% | 40% |
Documents
1
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Glenmark confirms it is not a Large Corporate under SEBI circular requirements. 30 Apr - Glenmark confirms it is not a Large Corporate under SEBI circular requirements.
2
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
30 Apr - Glenmark confirms it is not a Large Corporate under SEBI disclosure criteria. 30 Apr - Glenmark confirms it is not a Large Corporate under SEBI disclosure criteria.
3
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Glenmark confirms it is not a Large Corporate under SEBI circular requirements. 30 Apr - Glenmark confirms it is not a Large Corporate under SEBI circular requirements.
4
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
30 Apr - Glenmark confirms it is not a Large Corporate under SEBI disclosure criteria. 30 Apr - Glenmark confirms it is not a Large Corporate under SEBI disclosure criteria.
5
Announcement under Regulation 30 (LODR)-Press Release / Media Release
9 Apr - Glenmark receives U.S. FDA approval for Progesterone Vaginal Inserts, 100 mg; U.S. market sales ~$59.2 million. 9 Apr - Glenmark receives U.S. FDA approval for Progesterone Vaginal Inserts, 100 mg; U.S. market sales ~$59.2 million.
5
Letter To Shareholders Whose Email Address Are Not Registered Providing The Web Link Of Annual Report
13 Aug 2026
General_Announcements
Frequently Asked Questions about Glenmark Pharmaceuticals Ltd
What does Glenmark Pharmaceuticals Ltd do?
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]
Where is Glenmark Pharmaceuticals Ltd (GLENMARK) listed?
Glenmark Pharmaceuticals Ltd is listed on the Indian stock exchanges. It is listed on NSE: GLENMARK and BSE: 532296. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Glenmark Pharmaceuticals Ltd belong to?
Glenmark Pharmaceuticals Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd has a market capitalisation of approximately ₹65529.85 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Glenmark Pharmaceuticals Ltd?
The Price-to-Earnings (PE) ratio of Glenmark Pharmaceuticals Ltd is 36.18. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Glenmark Pharmaceuticals Ltd?
Over the past 52 weeks, Glenmark Pharmaceuticals Ltd has traded between a low of ₹1,792.6 and a high of ₹2,474. This range helps investors understand the stock's price volatility and recent trading levels.
Does Glenmark Pharmaceuticals Ltd pay dividends?
Yes, Glenmark Pharmaceuticals Ltd has a dividend yield of 0.21%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd has a Return on Equity (ROE) of 12.96%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Glenmark Pharmaceuticals Ltd on Tapetide?
On Tapetide, you can view Glenmark Pharmaceuticals Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]
Website glenmarkpharma.com
CEO Mr. Glenn Mario Saldanha
Employees 15,800
Listed 2000-02-07
Face Value ₹ 1
Issued Size 28,22,00,809